Your browser doesn't support javascript.
loading
Research protocol on early palliative care in patients with acute leukaemia after one relapse.
Barbaret, Cécile; Berthiller, Julien; Schott Pethelaz, Anne-Marie; Michallet, Mauricette; Salles, Gilles; Sanchez, Stéphane; Filbet, Marilène.
Afiliación
  • Barbaret C; Palliative Care, Clinique de Soins Palliatifs et Coordination de Soins de Support, Centre Hospitalo-Universitaire de Grenoble, Grenoble, Auvergne-Rhône-Alpes, France.
  • Berthiller J; Medical department, Université Joseph Fourier, Grenoble, France.
  • Schott Pethelaz AM; Clinical Research, Université Claude Bernard Lyon 1, HESPER unit EA 7425, Lyon, France.
  • Michallet M; Clinical Research, Hospices Civils de Lyon, Pôle IMER, Lyon, France.
  • Salles G; Clinical Research, Université Claude Bernard Lyon 1, HESPER unit EA 7425, Lyon, France.
  • Sanchez S; Clinical Research, Hospices Civils de Lyon, Pôle IMER, Lyon, France.
  • Filbet M; Hematology, Service d'Hématologie du centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, France.
BMJ Support Palliat Care ; 7(4): 480-484, 2017 Dec.
Article en En | MEDLINE | ID: mdl-28760818
ABSTRACT

OBJECTIVES:

According to the American Society of Clinical Oncology palliative care referrals are made within the last 3 weeks of patients' lives and most frequently when oncological treatments have ceased especially for patients with haematological malignancies. Recent publications indicate that patients with acute leukaemia are prone to symptoms, an indication for which a close collaboration between the patient's haematologist and a palliative care team might result in improved symptom management. The object of this pilot study is to evaluate the feasibility of a clinical research trial to assess the effect of early palliative care in patients with acute leukaemia after one relapse.

METHODS:

This project is a multicentre, non-blinded, randomised, controlled trial. Patients in group 1 will receive standard haematological care associated with palliative care (intervention group). Patients in group 2 will receive standard haematological care with palliative care only if requested by the haematologist (control group). In order to measure an accurate sample size, patients who participate will complete a standardised questionnaire to assess their quality of life, as well as their psychological and physical symptoms, before being randomised to one of two groups in a 11 ratio without stratified randomisation.

RESULTS:

The aim of this study is to analyse causes of dropout, non-adherence and missing data in order to refine the protocol for the subsequent clinical research trial.

CONCLUSION:

The ultimate objective of this project is to develop collaboration between haematologists and palliative care teams in order to improve patients' quality of life.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Cuidados Paliativos / Leucemia Mieloide Aguda / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudio: Clinical_trials / Guideline Límite: Humans Idioma: En Revista: BMJ Support Palliat Care Año: 2017 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Cuidados Paliativos / Leucemia Mieloide Aguda / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudio: Clinical_trials / Guideline Límite: Humans Idioma: En Revista: BMJ Support Palliat Care Año: 2017 Tipo del documento: Article País de afiliación: Francia